“Although Gregory received cutting edge immunotherapies and targeted therapies, including CAR-T 19 and an allogeneic CAR-T, the disease was very aggressive, and he succumbed to cancer,” explained Sonsy Rajan, Gregory’s mother and President of The Gregory Foundation For Cancer Research. Gregory was diagnosed with infant leukemia at the age of 10 months and fought the disease for 11 months.
The Gregory Foundation has a bold funding strategy. The Foundation believes that a single approach will not revolutionize or solve the lack of treatments in pediatric oncology. The Foundation is agnostic about the type of research, or the type of organization behind a promising project and invests in biotech companies. “We like projects and teams that tackle unmet needs in childhood cancer, combining drug development strategies in pediatric oncology with innovative and breakthrough technologies like Artificial Intelligence. All efforts are needed to reach the clinic faster and we acknowledge that Oncoheroes is aligned with our approach,” added Sonsy Rajan.
Oncoheroes Biosciences is a mission-driven biotech company building a multi-asset pipeline exclusively focused on pediatric oncology. To this end, we follow three different strategies:
Developing our drugs (2HIT Medulloblastoma) at our Discovery Lab.
In-licensing clinical stage or near clinical-stage drug candidates (volasertib).
Partnering with the pharmaceutical industry, foundations, and patient associations communities to support the development of novel therapies.
“Thank you to The Gregory Foundation for this second endorsement to Oncoheroes. We are impressed that The Gregory Foundation adopted, from the very beginning, a venture philanthropy approach. We are happy to see that more non-profits have recognized the role of an industry partner like Oncoheroes to develop new drugs for pediatric cancer. We look forward to continuing and building the partnership with The Gregory Foundation For Cancer Research,” stated Ricardo Garcia, Oncoheroes’ Co-Founder, and CEO.